Geneoscopy responds to Exact Sciences’ lawsuit moving forward 

The Missouri-based company sued by Exact Sciences for patent infringement is also praising the recent ruling of a judge in the case.

On Wednesday afternoon, Geneoscopy noted that the court dismissed Exact Sciences’ claim of infringement regarding a patent it uses for Cologuard, the Madison company’s colon cancer screening tool. The order directed Exact Sciences to file an amended complaint, and the company applauded the court on Tuesday for allowing the case to proceed.

Geneoscopy noted the court has not addressed or been asked to determine whether the patent in question is valid or enforceable.

“Geneoscopy is pleased with the court’s recent dismissal ruling, as we seek to ensure that Exact Sciences cannot impede innovation and advancement in the field of cancer detection by claiming exclusive rights to diagnostic methods it did not invent,” CEO Andrew Barnell said in a statement. “We are highly confident in the strength of our intellectual property.”

Barnell said they will continue their work to bring their product ColoSense to market. The cancer screening tool received Food and Drug Administration approval earlier this month, with plans for a commercial launch later this year or early next year.

Geneoscopy has separately asked the U.S. Patent and Trademark Office to launch a review of Exact Science’s patent.

The Missouri-based company called a second complaint filed against it by Exact Sciences last week alleging infringement on a related patent “likewise baseless” and that it will not disrupt commercialization plans for ColoSense.

This article first appeared in the Wisconsin Health News daily email newsletter. Sign up for your free trial here.